GlassScriptPhysician profile
Christine J Lawrence
NPI 1053750257
$9,660.98
in general payments reported to CMS, 2019-2025
33 companies · $634 in 2025
The $634 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,428 · 2020: $1,673 · 2021: $2,074 · 2022: $1,406 · 2023: $1,206 · 2024: $1,241 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,080.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,391.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $1,340.35 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $798.23 | 2019-2025 | Xifaxan |
| Lilly USA, LLC | $725.00 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $660.64 | 2021-2025 | |
| Pfizer INC. | $492.93 | 2019-2024 | |
| Glaxosmithkline, LLC. | $466.27 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $408.65 | 2019-2024 | |
| Abbvie INC. | $397.83 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $385.47 | 2019-2022 | |
| Amgen INC. | $317.29 | 2019-2024 | Repatha, Otezla |
| Allergan, INC. | $296.53 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.53 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Astrazeneca Pharmaceuticals LP | $242.44 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Paratek Pharmaceuticals, INC. | $173.84 | 2021-2024 | Nuzyra |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $155.08 | 2020-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Exact Sciences Corporation | $152.41 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Esperion Therapeutics, INC. | $146.22 | 2020-2024 | Nexletol |
| Nestle Healthcare Nutrition INC. | $133.32 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.31 | 2020-2021 | |
| Astellas Pharma US INC | $94.12 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $81.62 | 2020-2021 | |
| Daiichi Sankyo INC. | $70.43 | 2019-2022 | |
| Dexcom, INC. | $61.42 | 2022-2024 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $56.12 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $54.33 | 2022 | |
| Abbott Laboratories | $49.96 | 2021-2022 | |
| Lucid Diagnostics INC. | $42.05 | 2024 | |
| Insmed, INC. | $35.12 | 2021-2022 | |
| Almatica Pharma LLC | $22.72 | 2021 | |
| Phathom Pharmaceuticals, INC. | $15.91 | 2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $15.24 | 2023 | Linzess |
| Teva Pharmaceuticals USA, INC. | $11.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Lawrence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.